Journal article
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial
Abstract
OBJECTIVE: Diabetes mellitus (DM) is frequent among patients with atrial fibrillation (AF). The RE-LY trial permits evaluation of patient characteristics, outcomes and the effectiveness of dabigatran etexilate among diabetic individuals.
METHODS: Patient characteristics and outcomes were compared between diabetic and non-diabetic patients and the relative efficacy of each dose of dabigatran (150 mg bid and 110 mg bid) versus warfarin was …
Authors
Brambatti M; Darius H; Oldgren J; Clemens A; Noack HH; Brueckmann M; Yusuf S; Wallentin L; Ezekowitz MD; Connolly SJ
Journal
International Journal of Cardiology, Vol. 196, , pp. 127–131
Publisher
Elsevier
Publication Date
10 2015
DOI
10.1016/j.ijcard.2015.05.141
ISSN
0167-5273